Literature DB >> 3049951

Regimen-related toxicity in patients undergoing bone marrow transplantation.

S I Bearman1, F R Appelbaum, C D Buckner, F B Petersen, L D Fisher, R A Clift, E D Thomas.   

Abstract

Bone marrow transplantation is associated with significant morbidity and mortality, some of which is due to high-dose chemoradiotherapy. In order to quantitate toxicity that was felt to be due to the preparative regimen (termed regimen-related toxicity [RRT]), a system was developed in which toxicities were graded from 0 (none) to 4 (fatal). One hundred ninety-five patients who underwent marrow transplantation for leukemia were studied retrospectively to determine whether toxicities that were clinically felt to be due to the preparative regimen were influenced by other factors such as disease status, graft-versus-host disease (GVHD) prophylaxis, and allogenicity. All patients developed grade I toxicity in at least one organ, and 30 developed grades III-IV (life-threatening or fatal) RRT. RRT was more common in relapsed patients v remission patients (P = .04), in those receiving 15.75 Gy total body irradiation (TBI) v 12.0 Gy TBI (P = .028), and in those receiving allogeneic marrow v autologous marrow (P = .0029). Autologous marrow recipients did not develop grades III-IV toxicity in this study. A multivariate analysis controlling for autologous marrow grafting showed that the dose of TBI was the only statistically significant predictor of grades III-IV RRT. Those patients who developed grade III RRT were unlikely to survive 100 days from transplant, though not all deaths could be attributed to RRT. Patients who developed grade II toxicity in three or more organs were more likely to die within 100 days than those developing grade II toxicity in two or less organs (P = .0027). This system was generally able to distinguish RRT from other toxicities observed in marrow recipients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3049951     DOI: 10.1200/JCO.1988.6.10.1562

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  121 in total

1.  High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

Authors:  Peter A McSweeney; Richard A Nash; Keith M Sullivan; Jan Storek; Leslie J Crofford; Roger Dansey; Maureen D Mayes; Kevin T McDonagh; J Lee Nelson; Theodore A Gooley; Leona A Holmberg; C S Chen; Mark H Wener; Katherine Ryan; Julie Sunderhaus; Ken Russell; John Rambharose; Rainer Storb; Daniel E Furst
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 2.  Hematopoietic stem cell transplantation: a primer for the primary care physician.

Authors:  Chantal S Léger; Thomas J Nevill
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

3.  Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT).

Authors:  Michael J Kelly; Brian W Pennarola; Angie Mae Rodday; Susan K Parsons
Journal:  Pediatr Blood Cancer       Date:  2011-12-19       Impact factor: 3.167

Review 4.  Radioimmunotherapy in mantle cell lymphoma.

Authors:  Alan P Skarbnik; Mitchell R Smith
Journal:  Best Pract Res Clin Haematol       Date:  2012-05-09       Impact factor: 3.020

5.  Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy.

Authors:  Hirotaka Takasaki; Masatsugu Tanaka; Takayoshi Tachibana; Ayumi Numata; Katsumichi Fujimaki; Rika Sakai; Shin Fujisawa; Naoto Tomita; Hiroyuki Fujita; Atsuo Maruta; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2012-03       Impact factor: 2.490

6.  Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.

Authors:  Anthony Stein; Joycelynne Palmer; Ni-Chun Tsai; Monzr M Al Malki; Ibrahim Aldoss; Haris Ali; Ahmed Aribi; Len Farol; Chatchada Karanes; Samer Khaled; An Liu; Margaret O'Donnell; Pablo Parker; Anna Pawlowska; Vinod Pullarkat; Eric Radany; Joseph Rosenthal; Firoozeh Sahebi; Amandeep Salhotra; James F Sanchez; Tim Schultheiss; Ricardo Spielberger; Sandra H Thomas; David Snyder; Ryotaro Nakamura; Guido Marcucci; Stephen J Forman; Jeffrey Wong
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-10       Impact factor: 5.742

7.  Unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous transplantation for multiple myeloma.

Authors:  Toshiki Yamada; Akira Tomonari; Satoshi Takahashi; Jun Ooi; Tohru Iseki; Yoko Shimohakamada; Kashiya Takasugi; Nobuhiro Ohno; Fumitaka Nagamura; Kaoru Uchimaru; Arinobu Tojo; Hisataka Moriwaki; Shigetaka Asano
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

8.  Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.

Authors:  Amrita Y Krishnan; Joycelynne Palmer; Auayporn P Nademanee; Robert Chen; Leslie L Popplewell; Ni-Chun Tsai; James F Sanchez; Jennifer Simpson; Ricardo Spielberger; Dave Yamauchi; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-04       Impact factor: 5.742

9.  Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.

Authors:  Sakurako Izaki; Hiroaki Goto; Kumiko Okuda; Motoi Matsuda; Yuka Watanabe; Kenichirou Fujioka; Noriyuki Hanzawa; Hiroko Sumita; Hiroyuki Takahashi; Shoko Goto; Sumio Kai; Haruyuki Sekiguchi; Tetsunori Funabiki; Hideki Sasaki; Koichiro Ikuta; Shumpei Yokota
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

10.  Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation.

Authors:  Yasushi Takamatsu; Noriaki Sasaki; Tetsuya Eto; Koji Nagafuji; Yasunobu Abe; Ilseung Choi; Kentaro Ogata; Shuuji Hara; Junji Suzumiya; Kazuo Tamura
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.